Mercer Global Advisors Inc. ADV Purchases New Shares in Edwards Lifesciences Co. (NYSE:EW)

Mercer Global Advisors Inc. ADV acquired a new stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 121,385 shares of the medical research company's stock, valued at approximately $8,986,000.

A number of other large investors have also made changes to their positions in EW. Crowley Wealth Management Inc. purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $26,000. Millstone Evans Group LLC purchased a new stake in Edwards Lifesciences in the 4th quarter worth approximately $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Edwards Lifesciences in the 4th quarter valued at $30,000. Roble Belko & Company Inc purchased a new position in shares of Edwards Lifesciences during the 4th quarter worth $46,000. Finally, Catalyst Capital Advisors LLC acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $54,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 6,500 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.75, for a total value of $492,375.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,555,402. This represents a 12.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Bernard J. Zovighian sold 5,980 shares of Edwards Lifesciences stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $74.91, for a total value of $447,961.80. Following the transaction, the chief executive officer now directly owns 58,284 shares in the company, valued at approximately $4,366,054.44. The trade was a 9.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 77,833 shares of company stock worth $5,611,023. 1.29% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Morgan Stanley increased their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 12th. Piper Sandler raised shares of Edwards Lifesciences from a "neutral" rating to an "overweight" rating and raised their target price for the stock from $73.00 to $80.00 in a research report on Thursday, April 24th. Truist Financial dropped their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Wolfe Research lowered shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $85.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $79.45.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock traded down $0.17 on Tuesday, reaching $74.94. 2,378,625 shares of the company were exchanged, compared to its average volume of 5,019,167. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $95.25. The company's 50-day moving average is $71.23 and its two-hundred day moving average is $71.39. The firm has a market cap of $44.05 billion, a price-to-earnings ratio of 10.75, a P/E/G ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The company had revenue of $1.41 billion for the quarter, compared to analysts' expectations of $1.40 billion. During the same quarter in the previous year, the company posted $0.66 earnings per share. The business's revenue for the quarter was up 6.2% compared to the same quarter last year. As a group, research analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.